Research Analysts Issue Forecasts for Neurogene Q1 Earnings

Neurogene Inc. (NASDAQ:NGNE) – Stock analysts at Lifesci Capital dropped their Q1 2026 EPS estimates for Neurogene in a research report issued on Tuesday, March 24th. Lifesci Capital analyst P. Dolezal now forecasts that the company will post earnings per share of ($1.26) for the quarter, down from their previous estimate of ($1.19). Lifesci Capital currently has a “Outperform” rating and a $50.00 price target on the stock. The consensus estimate for Neurogene’s current full-year earnings is ($4.27) per share. Lifesci Capital also issued estimates for Neurogene’s Q2 2026 earnings at ($1.28) EPS, Q3 2026 earnings at ($1.04) EPS, Q4 2026 earnings at ($1.06) EPS and FY2026 earnings at ($4.59) EPS.

Several other brokerages also recently issued reports on NGNE. HC Wainwright reiterated a “buy” rating and issued a $70.00 target price on shares of Neurogene in a research note on Tuesday, January 13th. Canaccord Genuity Group initiated coverage on Neurogene in a research report on Friday, February 27th. They set a “buy” rating on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Neurogene in a research note on Thursday, January 22nd. Finally, Wall Street Zen cut Neurogene from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $44.00.

Neurogene Price Performance

Shares of NGNE opened at $22.03 on Thursday. The company has a market cap of $341.24 million, a PE ratio of -5.20 and a beta of 1.53. The firm has a 50-day moving average of $19.39 and a 200-day moving average of $21.65. Neurogene has a one year low of $6.88 and a one year high of $37.27.

Neurogene (NASDAQ:NGNE) last posted its quarterly earnings results on Tuesday, March 24th. The company reported ($1.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.20) by $0.08.

Institutional Investors Weigh In On Neurogene

Several hedge funds have recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Neurogene by 17.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock worth $82,000 after acquiring an additional 1,059 shares during the period. PNC Financial Services Group Inc. increased its stake in shares of Neurogene by 43.6% during the second quarter. PNC Financial Services Group Inc. now owns 4,055 shares of the company’s stock worth $61,000 after purchasing an additional 1,232 shares during the period. Schroder Investment Management Group acquired a new stake in Neurogene during the 2nd quarter worth approximately $451,000. Bank of America Corp DE lifted its holdings in Neurogene by 81.6% during the 2nd quarter. Bank of America Corp DE now owns 95,401 shares of the company’s stock worth $1,426,000 after purchasing an additional 42,880 shares during the last quarter. Finally, AlphaQuest LLC boosted its stake in Neurogene by 221.4% in the 3rd quarter. AlphaQuest LLC now owns 16,454 shares of the company’s stock valued at $285,000 after purchasing an additional 11,335 shares during the period. 52.37% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Stuart Cobb sold 6,797 shares of the stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $20.81, for a total value of $141,445.57. Following the transaction, the insider directly owned 30,497 shares of the company’s stock, valued at $634,642.57. This represents a 18.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Christine Mikail Cvijic sold 4,045 shares of the firm’s stock in a transaction dated Friday, March 13th. The stock was sold at an average price of $20.81, for a total transaction of $84,176.45. Following the sale, the chief financial officer owned 105,798 shares of the company’s stock, valued at approximately $2,201,656.38. This represents a 3.68% decrease in their position. The SEC filing for this sale provides additional information. 11.64% of the stock is owned by corporate insiders.

Neurogene Company Profile

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.